Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2010-10-08 Regulatory Filings
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text discusses a settlement of litigation related to a merger agreement between Emergent BioSolutions and Trubion Pharmaceuticals. It includes detailed supplemental disclosures to a Proxy Statement/Prospectus related to the merger, including background, reasons for the merger, and financial advisor opinions. The document is not a full annual or quarterly report, nor is it a proxy solicitation itself, but rather a current report announcing other events and providing supplemental information related to litigation and merger disclosures. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 8-K filings reporting material events.
2010-10-08 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text describes an amendment to a merger agreement between Emergent BioSolutions Inc. and Trubion Pharmaceuticals, including details about the termination of a 401(k) plan and references to the merger agreement. It also mentions the filing of a registration statement on Form S-4 and a definitive proxy statement related to the merger. The document is focused on merger-related information and amendments to merger agreements, which aligns with filings related to merger and acquisition activities. The presence of terms like 'Amendment No. 1 to Agreement and Plan of Merger' and detailed merger-related disclosures indicate this is a merger activity announcement rather than a full merger proxy statement or other report. Therefore, the appropriate classification is 'TAR' for M&A Activity, which covers announcements and documents related to merger proposals or takeover bids.
2010-09-30 English
8-K Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 29, 2010, reporting an amendment to a merger agreement between Emergent BioSolutions Inc. and Trubion Pharmaceuticals, Inc. The text discusses the amendment to the merger agreement, termination of retirement plans, and references the merger transaction. It also includes information about proxy statements and registration statements related to the merger. The document is primarily an announcement of a merger-related event and amendment, not a full merger proxy statement or detailed merger filing. It is not an annual report, earnings release, or other financial report. The content fits best under M&A Activity (TAR) as it relates to merger announcements and related documents. The document length is over 5,000 characters and contains substantive information about the merger amendment, not just a brief announcement or certification, so it is not RPA or RNS.
2010-09-30 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a contract modification with a government agency, specifically a no-cost extension of a contract period and delivery dates. There are no financial statements or detailed financial data presented. The document is relatively short (2424 characters) and focuses on a specific event rather than comprehensive financial results or management discussion. This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories like Annual Report or Earnings Release.
2010-09-28 English
424B3 Filing
Merger & Acquisition Classification · 100% confidence The document is a detailed proxy statement/prospectus related to a merger proposal between Trubion Pharmaceuticals, Inc. and Emergent BioSolutions Inc. It includes extensive information about the merger agreement, voting procedures, financial information, risk factors, legal matters, and annexes such as the merger agreement and financial statements. The document is filed pursuant to Rule 424(b)(3) and is part of a registration statement on Form S-4, which is typical for merger communications. The content and structure clearly indicate this is a merger-related filing, specifically a proxy statement/prospectus used to solicit shareholder approval for the merger. Therefore, the appropriate classification is Merger & Acquisition (MA).
2010-09-23 English
S-4/A Filing
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy statement/prospectus related to a merger proposal between Emergent BioSolutions Inc. and Trubion Pharmaceuticals, Inc. It includes detailed information about the merger agreement, voting procedures for stockholders, financial information, risk factors, and management discussion related to the merger. The document is filed as an amendment to Form S-4, which is used for registration of securities in connection with mergers and acquisitions. The presence of detailed merger terms, voting information, and proxy solicitation content indicates this is a Proxy Solicitation & Information Statement. It is not a full annual report, earnings release, or other financial report, but rather a document to solicit shareholder votes and provide information about the merger transaction.
2010-09-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.